Gilead's takeover of Forty Seven should soothe shareholders' worries

Gilean, the biopharma giant, is stocking up on potentially lucrative cancer drugs by snapping up smaller operators.

Biopharmaceutical giant Gilead Sciences has been facing “increasing unrest” from shareholders recently, says Josh Nathan-Kazis in Barron’s. They have been asking what it plans to do with its “substantial” amount of cash. Now they have their answer. Gilead has decided to buy “small cancer-focused biotech” Forty Seven for $4.9bn. Gilead hopes that the deal, which has boosted Forty Seven’s shares by 62%, will add “significant potential” to its clinical pipeline, particularly in the field of immuno-oncology, where the emphasis is on using the body’s own immune system to fight cancer. One particularly promising drug by Forty Seven is magrolimab, designed to treat several cancers, including myelodysplastic syndrome (in which some blood cells in bone marrow do not mature properly and become unhealthy) and a form of leukaemia.

Gilead needed to do something, say Marthe Fourcade and Kristen Brown on Bloomberg. While Gilead’s hepatitis C franchise may have turned the company into a “drug-industry giant”, sales of the treatments have “slipped from their peak” and the firm “has struggled to find new streams of revenue”. The deal with Forty Seven complements its 2017 acquisition of Kite Pharma, bringing on board “an experimental therapy that has potential to be the first in its class”. If Gilead hadn’t jumped on Forty Seven a competitor would probably have snapped it up; “other potential suitors” had been eyeing it up. 

Why cancer drugs are all the rage

Whether the deal proves a success or not, Gilead “is not alone” in turning to mergers and acquisitions to bolster its portfolio of cancer drugs, say Ortenca Aliaj and Eric Platt in the Financial Times. For example, early last year Bristol-Myers Squibb purchased Celgene for $93bn, while Pfizer snapped up Array BioPharma for $11bn in June. Rivals Eli Lilly and GlaxoSmithKline have also “bet billions of dollars” on cancer treatments over the past 18 months. The takeover of Forty Seven also “shares many of the hallmarks of other big cancer deals, where a recently listed start-up is acquired after its treatments show good progress in clinical trials”.

It’s not surprising that many companies are starting to invest in oncology, says Joseph Walker in The Wall Street Journal. Cancer drugs can “command high prices and receive relatively fast regulatory approvals”. US spending on cancer drugs has more than doubled to $56.7bn in 2018 from $27.3bn in 2013. Gilead has been working on an “experimental antiviral treatment which is being tested against... Covid-19”, says Robert Cyran on Breakingviews. However, it “can be hard to profit from epidemics because they are often short lived and always politically fraught”. As a result, it’s “always nice to have other options”, especially as Forty Seven’s price is “reasonable enough for a deal of this kind”.

Recommended

How to keep your dividends safe from the taxman
Personal finance

How to keep your dividends safe from the taxman

We look at ways to keep your dividends safe ahead of the decrease in tax allowances.
28 Mar 2023
Shoppers feel the pain as food inflation hits a record
Personal finance

Shoppers feel the pain as food inflation hits a record

Data from the analytics group Kantar showed food inflation hit a fresh peak in March 2023
28 Mar 2023
11 investment trusts for inflationary times
Investments

11 investment trusts for inflationary times

Inflation eats away at the value of your money, but these investment trusts can help you grow your wealth.
28 Mar 2023
Best junior stocks and shares ISA platforms
Isas

Best junior stocks and shares ISA platforms

A junior stocks and shares ISA is a great way to save for your child tax-efficiently. But it can be confusing deciding which investment platform to ch…
28 Mar 2023

Most Popular

Will energy prices go down in 2023?
Personal finance

Will energy prices go down in 2023?

Ofgem’s price cap is now predicted to fall below £2,000, based on average typical use, from July, for the first time since 2022. We have all the detai…
21 Mar 2023
Government plans could see NS&I boost interest rates
Savings

Government plans could see NS&I boost interest rates

The government-backed bank has a new funding target, which could prompt it to boost the rates on its Premium Bonds, ISAs and bonds.
16 Mar 2023
Where will house prices go in 2023?
House prices

Where will house prices go in 2023?

We explore what could happen to house prices in 2023 as the market continues to slow down.
24 Mar 2023